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A novel organic cation transporter OCTN2 is indispensable for carnitine transport across plasma membrane and subsequent fatty acid
metabolism in the mitochondria. Here, we report a novel splice variant of OCTN2 (OCTN2VT), in which a 72-base-pair sequence located in the
first intron of OCTN2 gene was spliced between exons 1 and 2 of OCTN2, causing the insertion of 24 amino acids in the first extracellular loop of
OCTN2. Despite the similarity between OCTN2 and OCTN2VT regarding primary structure and tissue distribution, their biochemical
characteristics were significantly different. OCTN2 was expressed on the plasma membrane with robust N-glycosylation, whereas OCTN2VTwas
retained in the endoplasmic reticulum (ER) with poor N-glycosylation. In addition, the retention in the ER caused no carnitine uptake into the
cells. These results demonstrate that the biochemical and functional characteristics of OCTN2VT are distinct from OCTN2 due to the insertion of
24 amino acids in the first extracellular loop.
© 2007 Elsevier B.V. All rights reserved.Keywords: OCTN2; OCTN2VT; Splicing; Carnitine; N-glycosylation; Endoplasmic reticulum1. Introduction
Carnitine (β-hydroxy-γ-trimethylamino butyrate) is essential
for transfer of long chain fatty acids from the cytosol to the
mitochondrial matrix for subsequent β-oxidation to generate
cellular energy [1]. The carnitine transport across the plasma
membrane is mediated by novel organic cation transporter
(OCTN) family proteins [2]. Three different OCTNs (OCTN1,
OCTN2, and OCTN3) have been identified in humans and mice
[3,4]. Among the OCTN family, OCTN2 has been shown to
transport carnitine most efficiently, and malfunction of OCTN2
causes the primary systemic carnitine deficiency characterized by
progressive cardiomyophathy, skeletal muscle myopathy, and
hypoglycemia in humans [5]. Themice having a pointmutation in⁎ Corresponding author. Tel.: +81 11 706 6919; fax: +81 11 706 7824.
E-mail address: smiwa@med.hokudai.ac.jp (S. Miwa).
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doi:10.1016/j.bbamcr.2007.04.005OCTN2 have severe disturbance of energy generation, causing
serious symptoms in the heart and skeletal muscles, in which fatty
acids are a primary source for energy [6]. Therefore, OCTN2 is
indispensable for energy homeostasis in the body.
The biochemical properties and physiological functions of
OCTN2 have been well established. OCTN2 transports carnitine
in a Na+-dependent manner [7]. OCTN2 is a twelve membrane-
spanning protein with three putative N-glycosylation sites
(Asn-57, -64, and -91) within the first extracellular loop [2].
Those sites are conserved in all members of an OCTN family
[8], suggesting that OCTN2 enters the secretory pathway
including endoplasmic reticulum (ER) and Golgi apparatus to
be expressed on the plasma membrane.
Recently, we identified a novel up-regulator of OCTN2, cartre-
gulin, in the rat brain [9]. Cartregulin is homologous to OCTN2,
and upregulates the expression level of OCTN2 by stabilizing the
mRNA of OCTN2. We also found a novel gene homologous to
OCTN2 by searching the human genome database “the Assembled
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insertion of 24 amino acids (QDSGAYNAMKNRMGKKPALCL-
PAQ) between Glu-131 and Trp-132 in the first extracellular loop
of OCTN2. This variant type of OCTN2 (designated as OCT
N2VT) was expected to possess the biochemical and physiological
characteristics similar to the OCTN2, because of the similarity
between OCTN2 and OCTN2VT regarding the primary structure.
However, the actual characteristics of OCTN2VT and the mecha-
nism by which OCTN2VT is produced are unknown.
In the present study, we attempted to elucidate these issues by
using HeLa cells stably expressing the yellow fluorescent pro-
tein (YFP)-tagged OCTN2VT. We found that despite the similar
expression profiles in the human tissues between OCTN2 and
OCTN2VT, their biochemical characteristics were significantly
different. That is, (1) OCTN2 was highly N-glycosylated and
expressed on the cell surface, whereas OCTN2VT was retained
in the ER without N-glycosylation; (2) OCTN2VT-expressed
HeLa cells could not take up carnitine due to the absence of
OCTN2VT on the plasma membrane; (3) the DNA sequence
encoding the 24 amino acids inserted in the OCTN2VT was
located in the first intron of OCTN2 genome with being inter-
posed between the GU-AG intron termini, suggesting the mech-
anism of the splicing to generate the OCTN2VT protein. Taken
together, these results demonstrate that OCTN2VT, a novelFig. 1. Identification of a splice variant of OCTN2. (A) Alignment of OCTN2 andOCT
in both amino acid sequence and the predicted secondary structure. The protein enc
indicated by asterisks. The putative transmembrane domains (TM1, TM2, and TM3)
illustrated. The genome sequence corresponding to the illustration is shown below. T
respectively. The GT-AG intron termini are shown in orange box. (C) Expression of O
arrows. Primers b and c are specific for OCTN2VT cDNA. (D) Tissue distribution of
references to colour in this figure legend, the reader is referred to the web version ofsplice variant of OCTN2, is biochemically and functionally
distinct from OCTN2 and other OCTN family proteins.
2. Materials and methods
2.1. Reagents and cell culture
Anti-GFP antibody (A.v. monoclonal antibody; clone JL-8) and anti-KDEL
antibody were purchased from Clontech (Mountain View, CA) and Stressgen
(Ann Arbor, MI), respectively. Peptide N-Glycosidase F (PNGase F) was pur-
chased from New England Biolabs (Beverly, MA). L-[methyl-3H]Carnitine HCl
was purchased from Amersham Biosciences (Sydney, Australia). HeLa cells
were grown in Dulbecco's modified Eagle's medium supplemented with 10%
fetal bovine serum.
2.2. PCR analysis
PCR was carried out by using human kidney cDNA library (Stratagene, La
Jolla, CA) as a template for 35 cycles (94 °C for 15 s, 55 °C for 30 s, and 72 °C for
2 min). Four types of primer designated primer a, b, c, and d were used (Fig. 1C).
Primer a (5′-CATGCGGGAGTACGACGAGGTGACC-3′) and primer d (5′-
TCTTTCCTCTTCAGTTTCTCCCTTA-3′) correspond to 5′- and 3′-ends of
OCTN2, respectively. Primer b (5′-GGCTTCTTTCCCATCCTGTTTTTCA-3′)
and primer c (5′-TACAATGCTATGAAAAACAGGATGG-3′) are reverse and
forward primers, respectively, corresponding to 3′- and 5′-ends of the insert
specific for OCTN2VT. The PCR products were subjected to gel electrophoresis
to determine the sizes of the products.N2VT proteins. The insertion of 24 amino acids in the OCTN2VT is shown in red
oded by exon 2 is shown in blue. The three putative N-glycosylation sites are
are shown in boxes. (B) OCTN2VT generated from splicing of OCTN2 gene is
he DNA sequences of the spliced region and exon 2 are shown in red and blue,
CTN2VT mRNA in the human kidney. Primers used for RT-PCR are shown by
OCTN2VT mRNA detected by northern blot analysis. (For interpretation of the
this article.)
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Northern blot analysis was done using MTN Multiple Tissue Northern Blot
(Human 12-Lane, Clontech, Mountain View, CA) as described previously [9]. A
72-bp fragment specific for OCTN2VT was used as a probe.
2.4. DNA constructs
The cDNAs encoding human OCTN2 and OCTN2VT were amplified by
PCR from the human kidney cDNA library. The N91Q mutation was introduced
by PCR-based site directed mutagenesis. Primers used here were 5′-CCACCA-
TCGCCCAGTTCTCGGCGCT-3′ and 5′-AGCGCCGAGAACTGGGC-
GATGGTGG-3′). The retroviral vectors for YFP-tagged OCTN2, OCTN2VT,
and OCTN2(N91Q) were constructed as described previously [10].
2.5. Analysis of expression level by flow cytometry and immunoblotting
Introduction of OCTN2YFP, OCTN2VTYFP, and OCTN2(N91Q)YFP into HeLa
cells was carried out by retroviral gene transfer as described previously [11]. The
cells stably expressing OCTN2YFP, OCTN2VTYFP, or OCTN2(N91Q)YFP were
selected by 2 μg/ml puromycin for 3 days. The expression levels of OCTN2YFP,
OCTN2VTYFP, and OCTN2(N91Q)YFP were determined by flow cytometric
analysis as described previously [11]. More than 95% of the cells expressed those
proteins. The whole cell lysates were prepared as described previously [12]. All
sampleswere loaded on gelswithout being boiled, becauseOCTN2 andOCTN2VT
were highly aggregated by the sample-boiling step. The membrane fractions were
prepared as described in Takaesu et al. [13]. The protein concentration of each
fractionwasmeasuredwith theBio-Rad ProteinAssay kit (Bio-Rad,Hercules, CA).
Equal amounts of protein were loaded in each lane and separated by SDS-
polyacrylamide gel electrophoresis. Gels were transferred onto Immobilon-P
membranes (Millipore, Bedford, MA), and blotted with anti-GFP antibody. In the
case of PNGase F treatment, 3 μg of OCTN2 membrane fraction and 50 μg of
OCTN2VTmembrane fraction were treated with PNGase F for 1 h at 37 °C. Then,
thewhole proteins were loaded and separated by SDS-PAGE. In the case ofMG132
treatment, HeLa cells retrovirally expressing OCTN2VTwere treated with 10 μM
MG132 for indicated periods, and then the whole cell lysates were prepared.
2.6. Microscopy
HeLa cells expressing OCTN2YFP or OCTN2VTYFP were plated onto a glass
bottom dish (IWAKI, Japan). Next day, the cells were fixed and permeabilized
with Cytofix/Cytoperm solution (BD Pharmingen, San Diego, CA). Then, the
cells were treated with anti-KDEL antibody followed by Alexa Fluor 594-
conjugated anti-mouse IgG antibody. After washes, subcellular distributions of
OCTN2YFP and OCTN2VTYFP were analyzed by Bio-Rad MRC1024 laser
scanning confocal microscope.
2.7. Transport study in HeLa cells
The transport activity ofOCTN2,OCTN2VT, orOCTN2(N91Q)wasmeasured
as described previously [9]. In brief, HeLa cells stably expressing YFP (vector
alone), OCTN2YFP, OCTN2VTYFP, OCTN2(N91Q)YFP in a 24-well plate were pre-
incubated in 0.2 ml of transport buffer (TB) [125 mMNaCl, 4.8 mMKCl, 5.6 mM
D-glucose, 1.2 mMCaCl2, 1.2 mMKH2PO4, 1.2 mMMgSO4, and 25 mMHEPES
(pH7.4)] for 10min at 37 °C, and transport reactionwas started by addition of 0.2ml
of TB containing 4 nM [3H]carnitine (81 Ci/mmol). After 7 min, the reaction was
terminated by aspiration of TB followed by five washes with 1 ml of ice-cold TB.
The amount of [3H]carnitine transported into the cells was counted with a liquid-
scintillation counter after solubilization of the cells with 0.5 ml of 1% SDS in 0.2 N
NaOH. Data were presented as means±SEM. A pair of means was compared with
Student's t-test. Groups of data were subjected to a two-way analysis of variance
(ANOVA), and when a significant F value was encountered, Newman–Keuls'
multiple-range test was used to test for significant differences between treatment
means. A probability level of Pb0.05 was considered statistically significant.
2.8. Genbank accession number
The accession number for human OCTN2VT is AB291606.3. Results and discussion
3.1. Isolation and tissue distribution of OCTN2VT
We have recently found a cDNA sequence encoding a
variant type of OCTN2 (OCTN2VT) in the database “AssEST”,
which is a clustered sequence database containing expressed
sequence tags and mRNA sequences in the public domain for
human, mouse, rat, and chicken. The putative open reading
frame of OCTN2VTwas composed of DNA sequence encoding
the full-length OCTN2 protein with a DNA-insertion for 24-
amino acids (QDSGAYNAMKNRMGKKPALCLPAQ). The
insertion was located between Glu-131 and Trp-132 in the first
extracellular loop of OCTN2 (Fig. 1A). We searched for the
location of the DNA sequence encoding the 24 amino acids in
the human genome and found that it was located in the first
intron of OCTN2 gene at the chromosome 5 (Fig. 1B). Inter-
estingly, this DNA sequence was interposed between AG and
GT (GU in mRNA) dinucleotides, both of which are conserved
sequences for splicing of mRNA precursors [14]. Because AG
and GU dinucleotides of mRNA precursors are recognized by
a spliceosome as a 3′- and 5′-ends of intron, respectively, it is
likely that in some case, a spliceosome might recognize the
DNA sequence encoding 24 amino acids as an additional exon,
leading to an insertion of its DNA sequence between exon 1 and
exon 2 to generate OCTN2VT mRNA.
To examine whether mRNA for OCTN2VT is actually ex-
pressed in human tissues,we performed PCRusing human kidney
cDNA library as a template and primers specific for OCTN2VT
cDNA.We used two sets of primers: one set corresponds to 5′-end
of OCTN2 cDNA and 3′-end of the insert (primers a and b), while
the other set corresponds to 5′-end of the insert and 3′-end of
OCTN2 cDNA (primers c and d). When these sets of primers
were used, PCR products with the expected size were obtained,
indicating that mRNA for OCTN2VT is actually expressed.
Therefore, we isolated the full-length OCTN2VT cDNA from
human kidney cDNA library with PCR. The sequence of the
PCR product was completely the same as that of the putative
OCTN2VT obtained from the AssEST database. The tissue
distribution of OCTN2VT mRNA studied by northern blotting
was similar to that of OCTN2 [2] except lower expression in the
kidney, indicating thatOCTN2VTmRNA is actually expressed in
human tissues, and that its gene expression may be regulated in a
similar manner to OCTN2.
3.2. OCTN2VT is not an N-glycosylated protein
The first extracellular loop of the OCTN2 is extremely large
compared to other extracellular loops (Fig. 1B), and the putative
N-glycosylation sites (Asn-57, -64, and -91) are present in this
loop [2], suggesting that the first extracellular loop may be
critical for the regulation of functional or biochemical properties
of OCTN2. Therefore, these properties of OCTN2VT may be
altered by the insertion of unique 24 amino acid sequence. First,
we investigated the biochemical properties of the OCTN2VT
in HeLa cells stably expressing OCTN2YFP or OCTN2VTYFP.
Interestingly, the expression level of OCTN2VT, which was
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fluorescent intensity of YFP as an index, was approximately
10% of the level for OCTN2, despite using the same retroviral
expression vector, pMXrmv5 [10] (Fig. 2A and B). The similar
result was observed in the immunoblotting (Fig. 2C). Notably,
detection of the OCTN2VT protein required a longer exposure
time than that of OCTN2. Because degradation of many pro-
teins is regulated by a ubiquitin-proteasome pathway, we exam-
ined whether the OCTN2VT was rapidly degraded by this
pathway. As shown in Fig. 2D, MG132, a selective 26S pro-
teasome inhibitor, had no effect on the protein level of the
OCTN2VT up to 12 h after its addition, suggesting that the
lower level of the OCTN2VT is not due to rapid degradation via
the ubiquitin-proteasome pathway.Fig. 2. Comparison of biochemical properties of OCTN2, OCTN2VT, and OCTN2(N
following transfection of cDNA. OCTN2 and OCTN2VT tagged with YFP (designat
vectors: in control cells, no transfection (designatedHeLa). Fluorescent intensity ofYFP
in each cell (ordinate) against FSC (abscissa) (A) or mean fluorescent intensity (MFI
expressing OCTN2YFP (WT) or OCTN2VTYFP (VT) by anti-GFP antibody. Left and
(D) Immunoblot analysis for changes of expression level of OCTN2VTYFP in HeLa
inhibitor. (E) Immunoblot analysis as in panel C. Unlike panel C, membrane fractions
were incubated with PNGase F for 1 h at 37 °C and subsequently subjected to SDS-PA
cells following transfection of cDNAwere analyzed by FACS.OCTN2VT was detected as a smaller protein (75 kDa) than
OCTN2 (90 kDa) on SDS-PAGE (Fig. 2C), although the
molecular weight of OCTN2VT calculated from its amino acid
sequence is apparently larger than that of OCTN2 because of the
insertion of 24 amino acids (Fig. 1A). Because OCTN2 pos-
sesses potential N-glycosylation sites on the first extracellular
loop, its larger molecular weight on SDS-PAGE seems to be due
to glycosylation of OCTN2. Thus, smaller molecular size of
OCTN2VT in comparison with OCTN2 might be due to less or
absent N-glycosylation of OCTN2VT.
To verify this point, we compared the apparent molecular
weights of OCTN2 and OCTN2VT after treatment of protein
extracts with PNGase F, an amidase that cleaves nearly all types
of oligosaccharides from glycoproteins. As shown in a right91Q). (A) and (B) Expression levels of OCTN2 and OCTN2VT in HeLa cells
ed OCTN2YFP and OCTN2VTYFP) were expressed in HeLa cells using retroviral
in each cell was analyzed byFACS, and represented as a plot of fluorescent intensity
) (B). (C) Immunoblot analysis of membrane fraction prepared from HeLa cells
right panels represent the results with a short or long exposure time, respectively.
cells following 4-h, 8-h, and 12-h treatment with 10 μM MG132, a proteasome
prepared from HeLa cells expressing OCTN2YFP (WT) and OCTN2VTYFP (VT)
GE. (F) and (G) Expression levels of OCTN2YFP and OCTN2(N91Q)YFP in HeLa
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became markedly smaller after treatment with PNGase F (from
90 kDa to 75 kDa), whereas the change in the apparent
molecular weight of OCTN2VT was very little. Consequently,
after treatment with PNGase F, the apparent molecular weight of
OCTN2 became nearly equal to that of OCTN2VT. These
results taken together indicate that the different apparent
molecular weights of OCTN2 and OCTN2VT reflect abundant
glycosylation of OCTN2 and poor glycosylation of OCTN2VT.
Because the insertion of 24 amino acids unique to OCTN2VT
was located in the same loop as N-glycosylation sites, this
insertion might block N-glycosylation in some way. To get
insights into the relationship between N-glycosylation and
expression level of OCTN2, we examined a mutant OCTN2
with one of the three potential N-glycosylation sites (Asn-91)
being replaced by glutamine (OCTN2(N91Q)): this site was
selected because it was the closest to the insertion of 24 amino
acids. The expression level of this mutant was found to be
reduced to about 50% of a wild type OCTN2 (Fig. 2F and G).
These results taken together suggest that N-glycosylation may
affect the expression level of OCTN2.
3.3. OCTN2VT is retained in the ER
During membrane trafficking for targeting to the plasma
membrane, most proteins enter the secretory pathway, i.e. ER and
Golgi apparatus, where the proteins are N-glycosylated [15].
Because OCTN2VT was minimally N-glycosylated (Fig. 2D),Fig. 3. Subcellular localization of OCTN2YFP (A) and OCTN2VTYFP (B). For
OCTN2VTYFP were first incubated with anti-KDEL antibody after fixation and perm
546-conjugated anti-mouse IgG for anti-KDEL antibody. After treatments, fluorescen
panels) were obtained using a Bio-Rad MRC1024 laser scanning confocal microscothere is the possibility that OCTN2VT cannot enter the secretory
pathway and hence it cannot reach the plasma membrane. To test
this possibility, we examined the subcellular localization of
OCTN2 and OCTN2VT in HeLa cells stably expressing these
molecules tagged with YFP. As shown in Fig. 3A, most of
OCTN2 proteins were present on the cell surface, indicating that
OCTN2 is expressed exclusively on the plasma membrane. In
contrast, OCTN2VT proteins were present mainly in the cyto-
plasm, and its subcellular localization was found to be consistent
with that of ER stained with anti-KDEL antibody, which specif-
ically recognizes proteins localized to ER (Fig. 3B), suggesting
that OCTN2VT is retained in ER. Since unglycosylated im-
mature proteins are known to remain in ER to be subjected to
proteolysis by the ER quality control system [16], it is likely that
OCTN2VTwhich is lacking N-glycosylation is degraded rapidly
because of its localization in ER.
3.4. OCTN2VT is a non-functional transporter for carnitine
To transport carnitine across the plasma membrane, OCTN
family proteins must be expressed on the cell surface. However,
since OCTN2VT was retained in the ER and not expressed on
the cell surface (Fig. 3), it is assumed that OCTN2VT is non-
functional as a transporter for carnitine. To test this, we measured
the activity of carnitine transport in HeLa cells stably expressing
OCTN2 and OCTN2VT. In comparison with the cells expressing
OCTN2, the cells expressing OCTN2VT showed a very low but
statistically significant level of carnitine transport activity: thestaining of endoplasmic reticulum, HeLa cells expressing OCTN2YFP and
eabilization of the cells, and subsequently, they were incubated with Alexa Fluor
t images of the cells derived from YFP (left panels) and Alexa Fluor 546 (middle
py. Right panels are merged images.
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were 658±9 and 603±6 dpm/3×105 cells, respectively (n=3,
Pb0.05) (Fig. 4A). The difference of these two values is a net
uptake via OCTN2VT, which is about 0.20% of the uptake via
OCTN2. After normalization of expression levels of OCTN2VT
byMFI, the uptake byOCTN2VT is still far lower than the uptake
by OCTN2. Considering that the MFI value obtained by FACS
Calibur reflects expression levels of OCTN2VT in whole areas of
individual cells but not on cell surface alone, and also that
OCTN2VT is localized mainly in cytosol, the transport activity of
each OCTN2VT molecule is estimated to be far higher than this
estimated value. Since it is at present difficult to estimate the
precise proportion of OCTN2VT expressed on the cell surface to
total OCTN2VT expressed in the whole cell, the actual transport
activity of eachOCTN2VTmolecule is unknown. Taken together,
these results indicate that a minute amount of OCTN2VT with a
carnitine transport activity is expressed, although it is unknown
whether the activity of each OCTN2VT molecule is normal or
reduced in comparison with that of wild type OCTN2.Fig. 4. Carnitine transport activity of OCTN2YFP, OCTN2VTYFP, and OCTN2(N91Q)
for either YFP (vector), OCTN2YFP, OCTN2VTYFP, and OCTN2(N91Q)YFP were inc
7 min at 37 °C. [3H]carnitine uptake into these cells were shown as mean±SEM (n=
present study.To examine the relationship among N-glycosylation, expres-
sion level, and transport activity of OCTN2, we also analyzed
the carnitine transport activity of OCTN2(N91Q): its expression
level was about half of OCTN2 (Fig. 2F and G) and most of it
was present on the cell surface (Fig. 4A, inset). The carnitine
uptake into the cells expressing OCTN2(N91Q) was about half
of OCTN2 (Fig. 4A). However, after normalization of its
expression level by MFI, the transport activity was found to be
not significantly different from the cells expressing OCTN2
(OCTN2(N91Q), 33.6±2.1×103 dpm/3×105 cells; OCTN2,
26.7±1.3×103 dpm/3×105 cells: PN0.05). These results imply
that the reduction of glycosylation affects the expression level
but not the transport activity of OCTN2.
A variety of mutations for OCTN2 have been reported in the
systemic carnitine deficiency (SCD) of humans [5,17–20]. The
Phe-17 to Leu mutation of OCTN2 identified in the SCD patient
showed a reduction of Vmax with no effect on Km for carnitine
transport due to its failure to be expressed on the cell surface [21].
Furthermore, Amat di San Filippo et al. have studied eightYFP. (A) HeLa cells stably transfected with expression vectors containing cDNAs
ubated with a saturating concentration (4 nM) of [3H]carnitine (81 Ci/mmol) for
3). Inset: the subcellular distribution of OCTN2(N91Q)YFP. (B) Summary of the
1006 S. Maekawa et al. / Biochimica et Biophysica Acta 1773 (2007) 1000–1006familieswith SCD and found several point mutations at sites other
than glycosylation sites, which caused significant retention of the
mutant OCTN2 in the cytoplasm [22]. Our results and these
reports suggest that the subcellular localization of the OCTN
family proteins is a critical factor for the pathogenesis of SCD.
Although it is not clear whether OCTN2VT transports
carnitine if expressed on the plasma membrane, its actual
function might transport organic cations across the ER mem-
brane. It would provide new insights into the physiological
functions of the OCTN family proteins to identify the substrate
molecules transported by OCTN2VT.
3.5. Concluding remarks
Although the OCTN family proteins have been thought to be
well conserved with respect to the biochemical and functional
characteristics, the OCTN2VT protein isolated in this study
showed unique characteristics, which are totally distinct from
the OCTN2 and other OCTN family proteins. Our results dem-
onstrate that OCTN2VT did not have the typical characteristics
of OCTN family proteins, such as an N-glycosylation and cell
surface expression, due to the insertion of 24 amino acids in the
first extracellular loop of OCTN2. Furthermore, the HeLa cells
expressing OCTN2VT proteins could not take up carnitine due
to the retention of OCTN2VT proteins in the ER. The insertion
of 24 amino acids may be made by the alternative splicing
because the DNA sequence encoding the 24 amino acids was
interposed between the conserved splice sites. Further investi-
gation into the physiological functions of OCTN2VT in the ER
may reveal the novel transport activity of OCTN family proteins
across the ER membrane as well as the plasma membrane.
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